[113mIn]In-PSMA: high potential agent for SPECT imaging of prostate cancer

The prevalence rate of prostate cancer is very high and unfortunately causes many deaths worldwide. This study aimed to prepare [ 113m In]In-PSMA as a novel agent for single photon emission computed tomography (SPECT) imaging of prostate cancer. 113m In was eluted from an in-house made 113 Sn/ 113m In generator in chloride form, and its radionuclide, chemical and radiochemical purities was studied. [ 113m In]In-PSMA was prepared with radiochemical purity (RCP) > 99 % under optimal labeling conditions. The biodistribution of the labeled compound was studied in normal rats, showed the major activity in the urine and kidneys as the main excretion route from the body. Considerable uptake was observed in the prostate and salivary glands as the PSMA-expressing organs. These data are in complete agreement with the other published data on PSMA-labeled compounds both in animals and humans. The results demonstrated [ 113m In]In-PSMA can be considered as a good option for SPECT imaging of prostate cancer.